- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01915121
An Educational Intervention for Patients With Bladder Cancer
An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society
The study main objectives are to enhance treatment decision making and improve quality of life and post-treatment health care among patients diagnosed with invasive bladder cancer.
Bladder cancer (BL Ca) is the 5th most commonly diagnosed cancer in the US . BL Ca is more common among men than women and 90% of all patients are over the age of 55. Surgery to remove the bladder followed by one of three diversion techniques (i.e., ileal conduit, continent reservoir, and neobladder) is the standard therapy following invasive bladder cancer. The emotional, functional, physical, and social impact of invasive Bl Ca treatment on patients' QOL and adjustment can be devastating. This impact significantly varies by treatment option. Treatment decision making in for BL Ca is difficult at best and potentially susceptible to a number of cognitive and affective factors (e.g., patients' emotional reaction, values, and expectations). Thus, in addition to adjusting to a potential life-threatening disease, having to cope with uncertainty about the efficacy and outcomes of different treatment options adds to the overall distress and may impair effective decision-making. In spite of increasing efforts in health communication and patient education, no study has examined treatment decision making among invasive bladder patients or has provided an educational intervention to facilitate treatment decision making among this population. To this end, and guided by the Self-Regulation theory (SRT) that emphasizes the role of cognitive and emotional factors in decision making, we have designed and pilot tested the acceptability of a preliminary educational and training experiential intervention (ETE) to address this gap in the literature. The ETE intervention uses new and innovative educational strategies and methods to educate patients about their treatment options and to facilitate their treatment decision making.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The goals of the study are: 1) to further enhance the design and application of the ETE intervention, and 2) to provide data on the efficacy of the refined ETE intervention in a randomized-controlled study (RCT). To achieve these 2 goals, the study is divided in to 2 phases.
PHASE 1: To enhance and refine the design and application of the preliminary ETE intervention:
Aim 1-a: To explore knowledge, beliefs, values and expectations about treatment options, treatment decision making, and quality of life (QOL) among patients with BL Ca.
To achieve Aim 1-a of Phase 1, as a first step, 2 focus groups (FG; N = 10 each) of invasive BL Ca patients will be conducted to a) examine knowledge, beliefs, values, expectations, and affective responses about treatment options and treatment decision making, b) record difficulties and problems in post-surgical health care (e.g., using stoma appliances and catheters), and c) explore concerns patients have as they live with the impact of treatment. The ETE intervention will be refined based on FG results.
Aim 1-b: To explore patients' acceptability of the refined ETE intervention. To achieve Aim 1-b of Phase 1, additional 2 FG (FG; N = 10 each) of BL Ca survivors will be conducted to solicit input about the design and acceptability of the refined ETE intervention.
PHASE 2: Aim 2. To assess the efficacy of the ETE intervention in small RCT To achieve Aim 2 of Phase 2, a two-group RCT (standard care (SC) plus time and attention control condition, N = 62 patients; SC plus ETE intervention N = 62 patients) will be conducted to examine the efficacy of the ETE intervention. Phase 2 will provide a) a test of the efficacy of the refined ETE intervention for reducing decisional conflict and regret, and improving QOL and post-treatment stoma and pouch care controlling for potential clinical and socio-demographic covariates (e.g., treatment type, age).
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
New York
-
New York, New York, Stati Uniti, 10029
- Icahn School of Medicine at Mount Sinai
-
The Bronx, New York, Stati Uniti, 10468
- James J. Peters VA Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Phase 1 (Focus groups/ In-depth Interview)
Inclusion Criteria:
- treatment of invasive Bladder Cancer a with cystectomy and one of the three major urinary diversion methods
- English speaking
- between the ages of 18 and 85
- able and willing to provide informed consent
- may have received neoadjuvant or adjuvant chemotherapy, radiation therapy, and immunotherapy (BCG)
Exclusion Criteria:
- metastatic disease or cancer recurrence
- presence of other primary cancers
- no access to a telephone
Phase 2 (randomized-controlled-study)
Additional Exclusion Criteria:
- treatment decision is made and /beginning/completion of treatment.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Education Intervention
In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
|
1-hour educational and training sessions.
In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended.
Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
|
|
Comparatore placebo: Nutrition Intervention
In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
|
1-hour educational and training sessions.
In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery.
In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended.
Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Decisional Regret Scale
Lasso di tempo: Baseline
|
The intervention is designed to enhance treatment decision making.
|
Baseline
|
|
Decisional Regret Scale
Lasso di tempo: 1 month follow up
|
The intervention is designed to enhance treatment decision making.
|
1 month follow up
|
|
Decisional Regret Scale
Lasso di tempo: 3 month follow up
|
The intervention is designed to enhance treatment decision making.
|
3 month follow up
|
|
Decisional Regret Scale
Lasso di tempo: 6 month follow up
|
The intervention is designed to enhance treatment decision making.
|
6 month follow up
|
|
Decisional Self-Efficacy Scale
Lasso di tempo: Baseline
|
The intervention is designed to enhance treatment decision making.
|
Baseline
|
|
Decisional Self-Efficacy Scale
Lasso di tempo: 1 month follow up
|
The intervention is designed to enhance treatment decision making.
|
1 month follow up
|
|
Decisional Self-Efficacy Scale
Lasso di tempo: 3 month follow up
|
The intervention is designed to enhance treatment decision making.
|
3 month follow up
|
|
Decisional Self-Efficacy Scale
Lasso di tempo: 6 month follow up
|
The intervention is designed to enhance treatment decision making.
|
6 month follow up
|
|
Treatment-related Values
Lasso di tempo: Baseline
|
The intervention is designed to enhance treatment decision making.
|
Baseline
|
|
Treatment-related Values
Lasso di tempo: 1 month follow up
|
The intervention is designed to enhance treatment decision making.
|
1 month follow up
|
|
Treatment-related Values
Lasso di tempo: 3 month follow up
|
The intervention is designed to enhance treatment decision making.
|
3 month follow up
|
|
Treatment-related Values
Lasso di tempo: 6 month follow up
|
The intervention is designed to enhance treatment decision making.
|
6 month follow up
|
|
Decisional Regret Scale
Lasso di tempo: Baseline
|
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making. |
Baseline
|
|
Decisional Regret Scale
Lasso di tempo: 1 month follow up
|
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making. |
1 month follow up
|
|
Decisional Regret Scale
Lasso di tempo: 3 month follow up
|
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making. |
3 month follow up
|
|
Decisional Regret Scale
Lasso di tempo: 6 month follow up
|
Bladder Cancer knowledge Scale The intervention is designed to enhance treatment decision making. |
6 month follow up
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
quality of life
Lasso di tempo: Baseline
|
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
|
Baseline
|
|
quality of life
Lasso di tempo: 1 month follow up
|
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
|
1 month follow up
|
|
quality of life
Lasso di tempo: 3 month follow up
|
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
|
3 month follow up
|
|
quality of life
Lasso di tempo: 6 month follow up
|
FACT-BL, Emotional, physical, function, and social Wellbeing Subscales
|
6 month follow up
|
|
post-surgical self-care
Lasso di tempo: Baseline
|
FACT-BL Ca additional concern
|
Baseline
|
|
post-surgical self-care
Lasso di tempo: 1 month follow up
|
FACT-BL Ca additional concern
|
1 month follow up
|
|
post-surgical self-care
Lasso di tempo: 3 month follow up
|
FACT-BL Ca additional concern
|
3 month follow up
|
|
post-surgical self-care
Lasso di tempo: 6 month follow up
|
FACT-BL Ca additional concern
|
6 month follow up
|
|
CES-D scale Illness Perception Questionnaire (IPQ)
Lasso di tempo: Baseline
|
Baseline
|
|
|
CES-D scale Illness Perception Questionnaire (IPQ)
Lasso di tempo: 1 month follow up
|
1 month follow up
|
|
|
CES-D scale Illness Perception Questionnaire (IPQ)
Lasso di tempo: 3 month follow up
|
3 month follow up
|
|
|
CES-D scale Illness Perception Questionnaire (IPQ)
Lasso di tempo: 6 month follow up
|
6 month follow up
|
|
|
Cancer worries scale
Lasso di tempo: Baseline
|
Baseline
|
|
|
Cancer worries scale
Lasso di tempo: 1 month follow up
|
1 month follow up
|
|
|
Cancer worries scale
Lasso di tempo: 3 month follow up
|
3 month follow up
|
|
|
Cancer worries scale
Lasso di tempo: 6 month follow up
|
6 month follow up
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Nihal E Mohamed, PhD, Icahn School of Medicine at Mount Sinai
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- GCO 09-0479
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro alla vescica
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.ReclutamentoCaregiving for CancerStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Institut Cancerologie de l'OuestAttivo, non reclutanteQualità della vita al lavoro | Professionisti paramedici | Toccare Massaggio | Cancer CenterFrancia
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
Yonsei UniversityNon ancora reclutamentoRAS/BRAF Wild-Type Advanced Cancer MathementCorea, Repubblica di
-
NRG OncologyNational Cancer Institute (NCI)CompletatoCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea del Sud
-
Jonsson Comprehensive Cancer CenterReclutamentoAdenocarcinoma prostatico | Cancro alla prostata in stadio II AJCC v8 | Fase I Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsReclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Second Affiliated Hospital, School of Medicine,...Attivo, non reclutanteElettroacopuntura combinata con paclitaxel legato alla proteina e anticorpo PD-1 per il trattamento di seconda linea di HER2 negativo, PMMR/MSS Advanced Gastric CancerCina
Prove cliniche su Education Intervention
-
Texas Tech UniversityCompletato
-
Nordsjaellands HospitalLund University; Region Capital Denmark; Ostfold University College; University College... e altri collaboratoriReclutamentoOspedaleDanimarca, Norvegia, Svezia
-
Tokat Gaziosmanpasa UniversityCompletatoStigmatizzazione | Funzionalità | Supporto tra pari | Disturbi mentali cronici | Formazione sulle abilità psicosociali | IntuizioneTacchino
-
Tulane UniversityUniversity of Alabama at Birmingham; Louisiana State University Health Sciences... e altri collaboratoriTerminatoCOVID-19 | Lupus eritematoso sistemicoStati Uniti
-
University of ZurichETH Zurich (Switzerland)Reclutamento
-
Superior UniversityAttivo, non reclutanteArtrosi al ginocchioPakistan
-
Oregon Health and Science UniversityNational Institute of Mental Health (NIMH); University of Connecticut; University... e altri collaboratoriNon ancora reclutamento
-
National University of Ireland, Galway, IrelandUniversity College Hospital Galway; Brothers of Charity Services Galway IrelandNon ancora reclutamentoDisabilità intellettive (F70-F79) | Educazione alla prevenzione e alla consapevolezza del cancro | Consapevolezza del cancro al senoIrlanda
-
Saglik Bilimleri UniversitesiNon ancora reclutamentoInvecchiamento | Anziani fragili | Sindromi geriatriche
-
Fundacion para la Investigacion y Formacion en...Iscrizione su invitoBPCO (broncopneumopatia cronica ostruttiva)Spagna